Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease

Chronic graft-versus-host disease (cGVHD) is an increasingly frequent cause of morbidity and mortality of allogeneic hematopoietic stem-cell transplantation. Sclerodermatous cGVHD (Scl-cGVHD) is characterized by fibrosis and autoimmune features resembling those of systemic sclerosis (SSc). Transplan...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 121; no. 16; pp. 3274 - 3283
Main Authors Le Huu, Doanh, Matsushita, Takashi, Jin, Guihua, Hamaguchi, Yasuhito, Hasegawa, Minoru, Takehara, Kazuhiko, Tedder, Thomas F., Fujimoto, Manabu
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 18.04.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chronic graft-versus-host disease (cGVHD) is an increasingly frequent cause of morbidity and mortality of allogeneic hematopoietic stem-cell transplantation. Sclerodermatous cGVHD (Scl-cGVHD) is characterized by fibrosis and autoimmune features resembling those of systemic sclerosis (SSc). Transplantation of B10.D2 bone marrow and splenocytes into irradiated BALB/c mice is an established model of human Scl-cGVHD. To examine the role of B cells in Scl-cGVHD, CD19-deficient (CD19−/−) mice were used as donors or recipients. CD19−/− donors induced more severe Scl-cGVHD than wild-type donors, but use of CD19−/− recipients resulted in no significant differences compared with wild-type recipients. Moreover, CD19 deficiency on donor B cells resulted in the expansion of splenic interleukin (IL) -6–producing monocytes/macrophages, cytotoxic CD8+ T cells, and Th1 cells during the early stage of disease and increased the infiltration of T cells, TGF-β–producing monocytes/macrophages, and Th2 cells into the skin in the later stage of Scl-cGVHD. IL-10–producing regulatory B cells (B10 cells) were not reconstituted by CD19−/− donor cells, and early adoptive transfer of B10 cells attenuated the augmented manifestations of CD19−/− donor-induced Scl-cGVHD. Therefore, donor-derived B10 cells have a suppressive role in Scl-cGVHD development, warranting future investigation of regulatory B-cell–based therapy for treatment of Scl-cGVHD and SSc. •CD19-deficient donors augmented Scl-cGVHD.•Donor regulatory B cells suppressed Scl-cGVHD.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2012-11-465658